Some companies are born out of necessity, or opportunity. See an underserved market, build a better mousetrap, etc. For Gilead Sciences (GILD) founder Michael Riordan, dengue fever was the mother of invention. Bitten by a mosquito and hospitalized for three weeks, nauseated, fatigued, and otherwise compromised, Riordan lamented the lack of drugs available for treating viruses such as that then inhabiting his bloodstream. So he decided to formulate one.

27 years later, Gilead is one of the quiet success stories of both medicine and Wall Street. The company now produces 16 drugs, which treat everything from cystic fibrosis (Cayston) to angina (Renexa.) Another couple of dozen treatments are on their way to market. The remainder of Gilead’s current roster combats pulmonary hypertension (Fiolan, Letairis), serious eye inflammations (Vistide, Macugen), fungal infections (AmBisone), and hepatitis B (Hepsera.) There’s also Lexiscan, a nuclear medicine treatment that opens blood vessels for examination. Gilead isn’t combating fibromyalgia and restless legs syndrome, but rather some of the most nefarious and insidious ailments around. (For related reading, see: What Are The Best Bets In Biotech?)

At The Forefront of Fighting HIV/AIDS

That leaves what are far and away Gilead’s two biggest moneymakers, HIV/AIDS drugs and flu treatments. The company produces no fewer than seven pharmaceuticals to fight HIV/AIDS, with prices ranging from $18 to $40 to $90 a pill. (There are multiple reasons why Gilead develops multiple HIV/AIDS drugs, contraindications being a major one.) When Michael Riordan was initially struck with a relatively tame viral infection, no one could predict that more impactful ones would become part of the landscape in the upcoming years. HIV/AIDS has since killed and rendered ill thousands of people, providing an opportunity for companies such as Gilead to capitalize upon. (If that sounds distasteful, consider the alternative – Gilead developing nothing.) (For related reading, see: Why There's Far More To Pfizer Than Viagra.)

Stacking The Deck

With the progress from drug development to public availability being famously sluggish in the United States, Riordan preemptively lured some of the most powerful people in Washington to serve as Gilead board members and executives. They include former cabinet secretaries Carla Hills, George Shultz and Donald Rumsfeld. For whatever reasons, Gilead drugs make it to market relatively quickly. Which dovetails with the story of what is perhaps Gilead’s most famous creation, Tamiflu. (For more, see: The Cost of Getting The Flu.)

In the mid-to-late 2000s, the fear of fatal contamination by “bird flu” swept much of the developed world. Even though bird flu cases were almost entirely restricted to rural parts of Southeast Asia, and numbered only in the dozens. Nevertheless, even with no reported cases in the United States, Tamiflu’s previous manufacturer sold tens of millions of doses to governments and non-governmental organizations. The United States Department of Health and Human Services authorized the purchase of $200 million worth of Tamiflu, in anticipation of an epidemic that still has yet to materialize. At the time, Gilead’s former chairman served as Secretary of Defense, sitting a chair or two away from the HHS Secretary.

Big R&D Spend

HIV/AIDS drugs are notoriously difficult to develop, and thus expensive. Which makes sense from an Economics 101 perspective too – create a product with enormous utility (saving the infected from what was formerly regarded as a death sentence), and a small but enthusiastic market (the vast majority of people don’t have HIV/AIDS), and said product won’t be cheap. (For related reading, see: Pharmaceutical Phenoms: America's Best-Selling Medicines.)

Gilead’s latest and potentially most profitable creation, Sovaldi, treats hepatitis C. Well, that’s an understatement. Sovaldi cures nine out of 10 patients, far more than any of the drug’s predecessors. Not only that, Sovaldi is a pill. (Previous hepatitis C treatments required the patient to administer a syringe.) Developing cirrhosis isn’t something you’d hope for, and Sovaldi provides a considerably more pleasant alternative. Even at $1,000 a pill.

That wasn’t a typo. And considering that a round of Sovaldi treatment consists of 84 pills, some insurance companies balk at covering it. Sovaldi’s sticker price might be shocking – as are those of other life-sustaining drugs – but you get what you pay for (freedom from future liver transplants). Still, lawmakers and bureaucrats in some current national governments, including that of the United States, decry Gilead for charging so much, even labeling its price “unsustainable.” The unintended consequences of this are clear. If Gilead anticipates that one day the price of Sovaldi will be set below the market clearing price by legislation (as has already happened in the United Kingdom, India and Egypt), the reasonable course of action is to charge as high a price as possible now. Furthermore, what distinguishes Sovaldi from other expensive drugs is that its customer base is relatively large. A dose of elaprase costs three times as much as a dose of Sovaldi, but the former treats a disease that an estimated 2,000 people worldwide suffer from. Tens of millions have hepatitis C. The result is that Sovaldi has generated $6 billion for Gilead so far, which represents what’s typically almost half a year’s revenue for the company. (For related reading, see: How Johnson & Johnson Became A Household Name.)

The Bottom Line

Many giant corporations’ contributions to society are tough to discern, or even justify. Some Wall Street titans offer financial liquidity, while there are others that offer rich tobacco satisfaction in smokable form. Fortunately, that still leaves plenty of room for a company whose objective, modus operandi, and mission are to save lives and ease discomfort around the world. (For more, see: Evaluating Pharmaceutical Companies.)

Related Articles
  1. Stock Analysis

    Healthcare M&A and Prescription Drug Prices

    Learn how mergers among health care insurance companies and drug companies could lead to increased premiums for consumers and lower drug costs.
  2. Investing Basics

    From Startup To Blue Chip: The Success Story Of Gilead Sciences Inc.

    Learn how Gilead Sciences went from a startup to one of the more successful pharmaceutical companies in the industry, and learn about its major drugs.
  3. Chart Advisor

    Gilead Sciences Inc

    For today's chart we've chosen to take a look at Gilead Sciences Inc. (Nasdaq:GILD) because it recently tested the strength of an influential level of resistance. As you can see from the chart ...
  4. Investing News

    3 Amazon Business Segments to Watch in 2016

    We'll look at three divisions of Amazon that are likely to perform well in 2016.
  5. Stock Analysis

    Elliott Management: An Activist Investor Analysis (HES, CTXS)

    Learn about the activist investor strategies used by Elliott Management. Read about the fund's positions in Hess Corp., Citrix and CDK Global.
  6. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  7. Stock Analysis

    The Top 5 Platinum Penny Stocks for 2016 (PLG, XPL)

    Examine five penny stocks in the platinum mining business that investors may wish to consider adding to their investment portfolios for 2016.
  8. Stock Analysis

    Forest Laboratories: An Activist Investment Analysis

    Find out how patience and perseverance paid off big-time for billionaire activist Carl Icahn during his four-year fight with Forest Laboratories.
  9. Investing News

    Zika: Study Says This Device Could Protect You

    New research just uncovered an inexpensive, commercially available device that might help fight off the mosquito that carries the dreaded Zika virus.
  10. Stock Analysis

    The Biggest Risks of Investing in Verizon Stock (VZ)

    Read about some of the biggest risks of investing in Verizon stock. While the company has a good dividend and value pricing, there are risks.
  1. What can working capital be used for?

    Working capital is used to cover all of a company's short-term expenses, including inventory, payments on short-term debt ... Read Full Answer >>
  2. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  3. Should I sell my shares if a company suspends its dividend?

    Since 2008, when the Federal Reserve slashed interest rates to zero and then kept them there indefinitely, dividend-paying ... Read Full Answer >>
  4. Do you include working capital in net present value (NPV)?

    Working capital is included in calculating the net present value (NPV) of a company. NPV is the difference between the present ... Read Full Answer >>
  5. Does working capital include marketable securities?

    Marketable securities represent highly liquid investments that are considered to be current assets and, therefore, are included ... Read Full Answer >>
  6. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
Trading Center